Rockefeller Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Rockefeller Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.11K	Hold	105	–	–	﹤0.01%	4286
2026 Q1	$2.84K	Hold	105	–	–	﹤0.01%	4350
2025 Q4	$4.5K	Hold	105	–	–	﹤0.01%	4109
2025 Q3	$2.98K	Buy	+105	New	+$3.14K	﹤0.01%	4009
2023 Q1	–	Sell	-105	Closed	-$1K	–	3496
2022 Q4	$1K	Hold	105	–	–	﹤0.01%	3742
2022 Q3	$1K	Hold	105	–	–	﹤0.01%	3773
2022 Q2	$1K	Hold	105	–	–	﹤0.01%	4001
2022 Q1	$3K	Sell	105 -100	-49%	-$2.71K	﹤0.01%	3524
2021 Q4	$5K	Sell	205 -37	-15%	-$1.12K	﹤0.01%	3287
2021 Q3	$8K	Sell	242 -50	-17%	-$1.97K	﹤0.01%	3002
2021 Q2	$12K	Hold	292	–	–	﹤0.01%	2715
2021 Q1	$9K	Buy	292 +142	+95%	+$5.62K	﹤0.01%	2651
2020 Q4	$5K	Hold	150	–	–	﹤0.01%	2446
2020 Q3	$3K	Hold	150	–	–	﹤0.01%	2361
2020 Q2	$3K	Hold	150	–	–	﹤0.01%	2250
2020 Q1	$2K	Hold	150	–	–	﹤0.01%	2208
2019 Q4	$3K	Hold	150	–	–	﹤0.01%	1878
2019 Q3	$3K	Buy	+150	New	+$3.1K	﹤0.01%	1742

Other funds holding RIGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's RIGL Position: Q2 2026 in Review

Rockefeller Capital Management held its Rigel Pharmaceuticals (RIGL) position steady in Q2 2026 at 105 shares worth $4.11K. The position accounts for ﹤0.01% of the portfolio, ranked #4286.

Rockefeller Capital Management first reported a position in RIGL in Q3 2019 and has held it in 18 quarters since. The position peaked at $12K in Q2 2021. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

Rockefeller Capital Management held 105 shares of Rigel Pharmaceuticals worth $4.11K as of Q2 2026.
Rockefeller Capital Management left its Rigel Pharmaceuticals share count unchanged in Q2 2026.
Rigel Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4286 holding.
Rockefeller Capital Management first reported a position in Rigel Pharmaceuticals in Q3 2019 and has held it in 18 quarters since.
Rockefeller Capital Management's Rigel Pharmaceuticals position peaked at $12K in Q2 2021.
155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.